P327 Evolution after a “de-intensification” strategy with anti-TNF therapy in patients with inflammatory bowel disease in clinical remission: multicenter study

Dialing Back M for Monoclonal: Successful De-escalation of Dose-Intensified Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease

“…The success rate of de-escalation of dose-intensified therapy was 63% and again no predictive factor was identified, likely due to small study numbers. While lack of power also precluded Little et al from identifying baseline predictors of successful de-escalation, a prior study published in abstract form was able to identify risk factors for failure, including the absence of concurrent immunomodulator therapy, a structuring or fistulizing Crohn's disease phenotype, previous IBD surgery, and extra-intestinal manifestations [8]. Of note, all of the patients in the study by Little et al received concomitant immunomodulator therapy.…”